Paper26057738
Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.
Tang W and 7 others. PLoS One, 2015. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis. Papers, record 26057738. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26057738
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Chemical and Drug Induced Liver Injury | Major topic |
| Hepatitis B | Major topic |
| Lamivudine | Major topic |
| Reverse Transcriptase Inhibitors | Major topic |
| Antineoplastic Agents | |
| Female | |
| Humans |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22973419 | Management of hepatitis B reactivation in patients receiving cancer chemotherapy. | Ther Adv Gastroenterol | 2012 | https://conductscience.org/library/papers/22973419 | PubMed |
| 2 | 17256718 | Chronic hepatitis B. | Hepatology | 2007 | https://conductscience.org/library/papers/17256718 | PubMed |
| 3 | 18302293 | A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. | Hepatology | 2008 | https://conductscience.org/library/papers/18302293 | PubMed |
| 4 | 14738558 | High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. | J Viral Hepat | 2004 | https://conductscience.org/library/papers/14738558 | PubMed |
| 5 | 9620341 | Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. | Hepatology | 1998 | https://conductscience.org/library/papers/9620341 | PubMed |
| 6 | 11753968 | Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. | Cancer | 2001 | https://conductscience.org/library/papers/11753968 | PubMed |
| 7 | 10502254 | Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. | J Med Virol | 1999 | https://conductscience.org/library/papers/10502254 | PubMed |
| 8 | 2629023 | Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. | Q J Med | 1989 | https://conductscience.org/library/papers/2629023 | PubMed |
| 9 | 10707871 | Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. | J Hepatol | 2000 | https://conductscience.org/library/papers/10707871 | PubMed |
| 10 | 23073741 | Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. | Breast Cancer | 2014 | https://conductscience.org/library/papers/23073741 | PubMed |
| 11 | 11722410 | Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. | Br J Haematol | 2001 | https://conductscience.org/library/papers/11722410 | PubMed |
| 12 | 11003630 | Long-term therapy of chronic hepatitis B with lamivudine. | Hepatology | 2000 | https://conductscience.org/library/papers/11003630 | PubMed |
| 13 | 15609123 | Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. | Breast Cancer Res Treat | 2004 | https://conductscience.org/library/papers/15609123 | PubMed |
| 14 | 21821601 | Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine. | Jpn J Clin Oncol | 2011 | https://conductscience.org/library/papers/21821601 | PubMed |
| 15 | 8781348 | Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. | Hepatology | 1996 | https://conductscience.org/library/papers/8781348 | PubMed |
| 16 | 11055239 | Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. | J Med Virol | 2000 | https://conductscience.org/library/papers/11055239 | PubMed |
| 17 | 15566502 | Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. | Liver Int | 2004 | https://conductscience.org/library/papers/15566502 | PubMed |
| 18 | 10458258 | Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10458258 | PubMed |
| 19 | 21285992 | Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21285992 | PubMed |
| 20 | 9636828 | Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. | Ann Oncol | 1998 | https://conductscience.org/library/papers/9636828 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42516138 | Establishment of prognostic nomogram in cervical cancer with hepatitis B virus infection: a retrospective study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42516138 | PubMed |
| 34621337 | COVID-19 Pandemic Impact on Cord Blood Collection for Stem Cell Use and Actual Perspectives. | Maedica (Bucur) | 2021 | https://conductscience.org/library/papers/34621337 | PubMed |
| 29637482 | Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. | Clin Rheumatol | 2018 | https://conductscience.org/library/papers/29637482 | PubMed |
| 27291888 | Prevention of Hepatitis B reactivation in the setting of immunosuppression. | Clin Mol Hepatol | 2016 | https://conductscience.org/library/papers/27291888 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26057738
GET https://conductscience.org/api/papers/v1/26057738/references?page=2